

2-23-04

Express Mail Label No.: EV 392154180 US
Date of Deposit: February 20, 2004

Attorney Docket No.: 18427-001 CON2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Sarvetnick, *et al.*
SERIAL: 10/672,685 EXAMINER: Not yet assigned
NUMBER:
FILING DATE: September 26, 2003 ART UNIT: 1641
FOR: PANCREATIC PROGENITOR CELLS AND METHODS FOR
ISOLATING THE SAME

Mail Stop IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate; and
3. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 18427-001 CON2. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

for Janine M. Susan, Reg. No. 46,119
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Dated: February 20, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Sarvetnick, *et al.*

SERIAL
NUMBER: 10/672,685

EXAMINER: Not yet assigned

FILING DATE: September 26, 2003

ART UNIT: 1641

FOR: PANCREATIC PROGENITOR CELLS AND METHODS FOR ISOLATING
THE SAME

Mail Stop IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required. Copies of the references are not provided as they were previously cited and/or submitted to the USPTO in prior applications, Serial No. 09/826,779, filed April 5, 2001, and Serial No. 09/212,531, filed December 16, 1989, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications). Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 18427-001 CON2.

Respectfully submitted,

for Janine M. Susan, Reg. No. 46,119
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Dated: February 20, 2004



Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO				Application Number		10/672,685	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date		September 26, 2003	
				First Named Inventor		Sarvetnick	
				Group Art Unit		1641	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		18427-001 CON2	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	**5,849,989	12/15/98	Edlund	800	2	
	A2	**5,858,973	01/12/99	Habener, et al.	514	12	
	A3	**6,326,201 B1	12/04/01	Fung, et al.	435	377	
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	*WO 98/26044	The Regents of The University of California	06/18/98			
	B2	*WO 96/11949	Amgen, Inc.	04/25/96			
	B3	*WO 96/40872	Ontogeny, Inc.	12/19/96			
	B4	*WO 98/16243	Amgen, Inc.	04/23/98			
	B5	*EP 0 363 125	Hana Biologics, Inc.	04/11/90			
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	*Amush <i>et al.</i> , "Growth factors in the regenerating pancreas of gamma-interferon transgenic mice," <i>Lab. Invest.</i> 74: 985-990 (1996).					
	C2	*Gu <i>et al.</i> , "Epithelial cell proliferation and islet neogenesis in IFN-g transgenic mice," <i>Development</i> , 118: 33-46 (1993).					
	C3	*Guo <i>et al.</i> , "Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice," <i>EMBO J.</i> , 12: 973-986 (1993).					
	C4	*Housley <i>et al.</i> , "Keratinocyte growth factor induces proliferation of hepatocytes and, epithelial cells throughout the rat gastrointestinal tract," <i>J. Clin. Invest.</i> , 94: 1764-1777 (1994).					
	C5	*Nguyen, <i>et al.</i> , "Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations," <i>Oncogene</i> , 12: 2109-2119 (1996).					
	C6	*Sarvetnick <i>et al.</i> , "Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class III MHC and interferon-gamma," <i>Cell</i> , 52: 773-782 (1988).					
	C7	*Yi <i>et al.</i> , "Keratinocyte growth factor induces pancreatic ductal epithelial proliferation," <i>Am. J. Pathol.</i> , 145: 80-85 (1994).					
	C8	*Peshavaria & Stein, <i>Pancreatic Growth and Regeneration</i> , Chapter 4, Sarvetnick, ed. (Karger Lander Systems, 1997).					
	C9	*Jones & Sarvetnick, 29, <i>Horm. Metab. Res.</i> , 308-310 (1997).					
	C10	*Krakowski <i>et al.</i> , 162, <i>J. Endocrinology</i> , 167-175 (1999).					
	C11	*Kritzik <i>et al.</i> , 163, <i>J. Endocrinology</i> , 523-530 (1999).					
	C12	*Krakowski <i>et al.</i> , 154(3), <i>Am. J. Pathology</i> , 683-691 (March 1999).					
	C13	*Ebert, <i>et al.</i> , <i>Mol. Endocrinol.</i> , 2:277-283 (1988).					
	C14	*Wall, <i>et al.</i> , <i>J. Dairy Sci.</i> , 80(9):2213-2224 (1997).					
	C15	*Tasuda, <i>et al.</i> , <i>J. Biol. Chem.</i> , 273(51):34413-34421 (1998).					
	C16	*Hammer, <i>et al.</i> , <i>J. Anim. Sci.</i> , 63:269-278 (1986).					
	C17	*Itier, <i>et al.</i> , <i>Differentiation</i> , 60:309-316 (1996).					

C18	*Mullins, et al., <i>J. Clin. Invest.</i> , 97(7):1557-1560 (1996).
C13	**O'Reilly, et al., <i>Diabetes</i> , 46:599-606 (1997).
C14	**Fernandes, et al., <i>Endocrinol.</i> , 138:1750-1762 (1997).

* copies of these references are not provided as they were previously cited by or submitted to the U.S. Patent Office in a prior application, **Serial No. 09/212,531, filed December 16, 1998**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

** copies of these references are not provided as they were previously cited by or submitted to the U.S. Patent Office in a prior application, **Serial No. 09/826,779, filed April 5, 2001**, which is a Continuing Application of **Serial No. 09/212,531, filed December 16, 1998**, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1887751v1